Literature DB >> 25775525

Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells.

Emma M Carrington1, Jian-Guo Zhang1, Robyn M Sutherland1, Ingela B Vikstrom1, Jamie L Brady1, Priscilla Soo2, David Vremec2, Cody Allison1, Erinna F Lee1, W Douglas Fairlie1, Philippe Bouillet1, Stephanie Grabow1, Eleonora Ottina3, Marco J Herold1, Marc Pellegrini1, David C S Huang1, David M Tarlinton1, Andreas Strasser1, Andrew M Lew4, Yifan Zhan5.   

Abstract

Dendritic cells (DCs) are heterogeneous, comprising subsets with functional specializations that play distinct roles in immunity as well as immunopathology. We investigated the molecular control of cell survival of two main DC subsets: plasmacytoid DCs (pDCs) and conventional DCs (cDCs) and their dependence on individual antiapoptotic BCL-2 family members. Compared with cDCs, pDCs had higher expression of BCL-2, lower A1, and similar levels of MCL-1 and BCL-XL. Transgenic overexpression of BCL-2 increased the pDC pool size in vivo with only minor impact on cDCs. With a view to immune intervention, we tested BCL-2 inhibitors and found that ABT-199 (the BCL-2 specific inhibitor) selectively killed pDCs but not cDCs. Conversely, genetic knockdown of A1 profoundly reduced the proportion of cDCs but not pDCs. We also found that conditional ablation of MCL-1 significantly reduced the size of both DC populations in mice and impeded DC-mediated immune responses. Thus, we revealed that the two DC types have different cell survival requirements. The molecular basis of survival of different DC subsets thus advocates the antagonism of selective BCL-2 family members for treating diseases pertaining to distinct DC subsets.

Entities:  

Keywords:  BH3-mimetic; apoptosis; dendritic cells

Mesh:

Substances:

Year:  2015        PMID: 25775525      PMCID: PMC4386329          DOI: 10.1073/pnas.1417620112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

Review 1.  Decisions about dendritic cells: past, present, and future.

Authors:  Ralph M Steinman
Journal:  Annu Rev Immunol       Date:  2011-11-17       Impact factor: 28.527

2.  BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs.

Authors:  Emma M Carrington; Ingela B Vikstrom; Amanda Light; Robyn M Sutherland; Sarah L Londrigan; Kylie D Mason; David C S Huang; Andrew M Lew; David M Tarlinton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

3.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

4.  Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual.

Authors:  Melissa Swiecki; Susan Gilfillan; William Vermi; Yaming Wang; Marco Colonna
Journal:  Immunity       Date:  2010-12-02       Impact factor: 31.745

5.  The transcription factor Spi-B regulates human plasmacytoid dendritic cell survival through direct induction of the antiapoptotic gene BCL2-A1.

Authors:  Julien J Karrich; Melania Balzarolo; Heike Schmidlin; Marion Libouban; Maho Nagasawa; Rebecca Gentek; Shimeru Kamihira; Takahiro Maeda; Derk Amsen; Monika C Wolkers; Bianca Blom
Journal:  Blood       Date:  2012-04-17       Impact factor: 22.113

6.  Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC.

Authors:  Henning Lauterbach; Barbara Bathke; Stefanie Gilles; Claudia Traidl-Hoffmann; Christian A Luber; György Fejer; Marina A Freudenberg; Gayle M Davey; David Vremec; Axel Kallies; Li Wu; Ken Shortman; Paul Chaplin; Mark Suter; Meredith O'Keeffe; Hubertus Hochrein
Journal:  J Exp Med       Date:  2010-10-25       Impact factor: 14.307

7.  Type I interferon drives dendritic cell apoptosis via multiple BH3-only proteins following activation by PolyIC in vivo.

Authors:  Silvia A Fuertes Marraco; Clare L Scott; Philippe Bouillet; Annette Ives; Slavica Masina; David Vremec; Elisa S Jansen; Lorraine A O'Reilly; Pascal Schneider; Nicolas Fasel; Ken Shortman; Andreas Strasser; Hans Acha-Orbea
Journal:  PLoS One       Date:  2011-06-02       Impact factor: 3.240

8.  Batf3-dependent CD11b(low/-) peripheral dendritic cells are GM-CSF-independent and are not required for Th cell priming after subcutaneous immunization.

Authors:  Brian T Edelson; Tara R Bradstreet; Wumesh KC; Kai Hildner; Jeremy W Herzog; Julia Sim; John H Russell; Theresa L Murphy; Emil R Unanue; Kenneth M Murphy
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

9.  Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway.

Authors:  P E Cippà; A K Kraus; M T Lindenmeyer; J Chen; A Guimezanes; P D Bardwell; T Wekerle; R P Wüthrich; T Fehr
Journal:  Cell Death Dis       Date:  2012-04-19       Impact factor: 8.469

10.  Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice.

Authors:  Eleonora Ottina; Francesca Grespi; Denise Tischner; Claudia Soratroi; Stephan Geley; Andreas Ploner; Holger M Reichardt; Andreas Villunger; Marco J Herold
Journal:  Blood       Date:  2012-05-11       Impact factor: 22.113

View more
  24 in total

1.  Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment.

Authors:  Robyn L Schenk; Selma Tuzlak; Emma M Carrington; Yifan Zhan; Susanne Heinzel; Charis E Teh; Daniel H Gray; Lin Tai; Andrew M Lew; Andreas Villunger; Andreas Strasser; Marco J Herold
Journal:  Cell Death Differ       Date:  2017-01-13       Impact factor: 15.828

2.  The BCL-2 pro-survival protein A1 is dispensable for T cell homeostasis on viral infection.

Authors:  Selma Tuzlak; Robyn L Schenk; Ajithkumar Vasanthakumar; Simon P Preston; Manuel D Haschka; Dimitra Zotos; Axel Kallies; Andreas Strasser; Andreas Villunger; Marco J Herold
Journal:  Cell Death Differ       Date:  2017-01-13       Impact factor: 15.828

3.  Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo.

Authors:  Emma M Carrington; Yifan Zhan; Jamie L Brady; Jian-Guo Zhang; Robyn M Sutherland; Natasha S Anstee; Robyn L Schenk; Ingela B Vikstrom; Rebecca B Delconte; David Segal; Nicholas D Huntington; Philippe Bouillet; David M Tarlinton; David Cs Huang; Andreas Strasser; Suzanne Cory; Marco J Herold; Andrew M Lew
Journal:  Cell Death Differ       Date:  2017-03-31       Impact factor: 15.828

4.  Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.

Authors:  Joan Montero; Jason Stephansky; Tianyu Cai; Gabriel K Griffin; Lucia Cabal-Hierro; Katsuhiro Togami; Leah J Hogdal; Ilene Galinsky; Elizabeth A Morgan; Jon C Aster; Matthew S Davids; Nicole R LeBoeuf; Richard M Stone; Marina Konopleva; Naveen Pemmaraju; Anthony Letai; Andrew A Lane
Journal:  Cancer Discov       Date:  2016-12-16       Impact factor: 39.397

Review 5.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Authors:  Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai
Journal:  Cancer Discov       Date:  2017-11-16       Impact factor: 39.397

Review 6.  The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules.

Authors:  Emma M Carrington; David M Tarlinton; Daniel H Gray; Nicholas D Huntington; Yifan Zhan; Andrew M Lew
Journal:  Immunol Cell Biol       Date:  2017-09-06       Impact factor: 5.126

Review 7.  What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?

Authors:  Kerstin Brinkmann; Ashley P Ng; Carolyn A de Graaf; Andreas Strasser
Journal:  Cell Death Differ       Date:  2022-04-06       Impact factor: 12.067

8.  The immune landscape in tuberculosis reveals populations linked to disease and latency.

Authors:  Ekaterina Esaulova; Shibali Das; Dhiraj Kumar Singh; Jose Alberto Choreño-Parra; Amanda Swain; Laura Arthur; Javier Rangel-Moreno; Mushtaq Ahmed; Bindu Singh; Ananya Gupta; Luis Alejandro Fernández-López; Maria de la Luz Garcia-Hernandez; Allison Bucsan; Chivonne Moodley; Smriti Mehra; Ethel García-Latorre; Joaquin Zuniga; Jeffrey Atkinson; Deepak Kaushal; Maxim N Artyomov; Shabaana A Khader
Journal:  Cell Host Microbe       Date:  2020-12-18       Impact factor: 31.316

9.  Phenotypic and functional alterations of pDCs in lupus-prone mice.

Authors:  Zhenyuan Zhou; Jianyang Ma; Chunyuan Xiao; Xiao Han; Rong Qiu; Yan Wang; Yingying Zhou; Li Wu; Xinfang Huang; Nan Shen
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

10.  Plasmacytoid dendritic cells are short-lived: reappraising the influence of migration, genetic factors and activation on estimation of lifespan.

Authors:  Yifan Zhan; Kevin V Chow; Priscilla Soo; Zhen Xu; Jamie L Brady; Kate E Lawlor; Seth L Masters; Meredith O'keeffe; Ken Shortman; Jian-Guo Zhang; Andrew M Lew
Journal:  Sci Rep       Date:  2016-04-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.